Pramodini Medicare IPO
Pramodini Medicare IPO Listing Day Performance
Pramodini Medicare listed on NSE SME on 19 August 2026 at ₹120.00, a 1.69% premium over the issue price of ₹118. A retail investor allotted the minimum application of 2,400 shares (2 lots) gained ₹4,800 at the listing price.
Demand going into listing
| Subscribed overall | 3.95× |
| QIB | 3.66× |
| NII | 5.31× |
| Retail | 3.47× |
Market Sentiment
The overall score is a weighted average of the parts below, so one weak part can sit inside a strong overall reading.
IPO Details
Day-wise Subscription (times subscribed)
| Category | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| QIB | 1.81x | 1.81x | 3.66x |
| NII | 0.23x | 0.56x | 5.31x |
| bNII > ₹10L | 0.26x | 0.63x | 5.55x |
| sNII 2-10L | 0.15x | 0.41x | 4.82x |
| Retail | 0.39x | 0.71x | 3.47x |
| Total | 0.69x | 0.91x | 3.95x |
Market Lot Size
IPO Reservation
Financial Analysis
Financial Data
Financial Performance
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 35.79 | 38.55 | 63.38 |
| Expense | 25.72 | 22.80 | 40.08 |
| Profit (PAT) | 7.14 | 11.14 | 17.38 |
| Total Assets | 48.78 | 56.45 | 93.62 |
Peer Comparison
| Company | EPS | P/E | RoNW % | NAV |
|---|---|---|---|---|
| Pramodini Medicare This IPO | 10.41 | - | 32.69 | 31.84 |
| Invicta Diagnostic Limited | 4.90 | 13.62 | 9.76 | 39.71 |
| Krsnaa Diagnostics Limited | 31.30 | 16.74 | 10.35 | 302.23 |
| Star Imaging & Path Labs Limited | 11.05 | 7.87 | 16.58 | 66.65 |
Strengths & Risks
- Strong institutional (QIB) demand — 3.7x.
- Revenue grew 64% in the latest reported year.
- Solid profit margin — 27.4%.
- Strong return on equity — 39%.
- Low leverage — debt/equity of 0.34.
- Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
About Pramodini Medicare
Pramodini Medicare Limited, founded in 2000, is one of the leading diagnostic services providers in India across radiology, clinical laboratory, and nuclear medicine segments. Its service portfolio includes radiology services such as MRI, CT scans, X-ray, ultrasound with colour Doppler, mammography, DEXA scan, and interventional radiology; clinical laboratory services including haematology, microbiology, immunology, pathology, and biochemistry; and nuclear medicine services such as PET-CT, SPECT, and nuclear therapy. Pramodini Medicare operates diagnostic centres through Public-Private Partnerships (PPP), Private-Private Partnerships (Pvt-Pvt), Strategic Partnerships with PSUs, Standalone Diagnostic Centres, and Location-Specific Agreements. The firm has its presence across Vijayawada, Hyderabad, Kurnool, Kapada, Tirupati, Varanasi, Prayagraj, and many others.
Company Contact Information
Pramodini Medicare Ltd., D. No: – 29-4-54K, CSI Complex,, Prakasam Road,, Suryaraopet, Vijayawada, Andhra Pradesh, 520002
Objects of the Issue
| Purpose | Amount (Cr) |
|---|---|
| Funding of capital expenditure for purchase of Medical Equipments towards Existing and Proposed Diagnostic Centres | 45.15 |
| General corporate purposes and unidentified inorganic acquisition | - |
Resources & Documents
Anchor Investors
Pramodini Medicare IPO - Quick Take
Pramodini Medicare has set a price band of Rs 110–Rs 118 per share for an issue size of Rs 69 crore. The stock listed with a 1.69% gain versus its issue price on August 19, 2026.
The issue is promoted by Dr. Chalasani Kuldeep Kumar, Dr. Chalasani Kavitha, Ms. Chalasani Durga Aashritha and M/s. Sri Ram Medicare Private Limited with Smart Horizon Capital Advisors Pvt.Ltd. acting as lead manager. Net proceeds will primarily be used towards funding of capital expenditure for purchase of Medical Equipments towards Existing and Proposed Diagnostic Centres (Rs 45 crore) and general corporate purposes and unidentified inorganic acquisition.
On fundamentals, the company is posting revenue growth of 64.4%, a profit margin of 27.4%, return on equity of 39.1% in its most recent reported period. Listed peers in this segment include Invicta Diagnostic Limited (P/E 13.62x) and Krsnaa Diagnostics Limited (P/E 16.74x) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
On our data-signal score, the combined signals for this issue currently read mixed — some indicators read positively and others do not. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Frequently Asked Questions
Pramodini Medicare IPO GMP — What It Means
GMP stops mattering once the shares trade — it only ever estimated the listing price. No grey market premium was recorded for Pramodini Medicare before it listed.
See the full Pramodini Medicare GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
Same sector or same stage as Pramodini Medicare
No comments yet. Be the first to share your opinion!